Related Experiment Videos
[Pharmacology aspects of glaucoma]
1Institutionen för oftalmiatrik, Ogonkliniken, Akademiska Sjukhuset, Uppsala.
Nordisk Medicin
|January 1, 1992
Summary
Glaucoma treatment aims to reduce eye pressure. Beta-blockers like timolol maleate now lead, replacing older cholinergic agonists, with new drugs in trials.
Area of Science:
- Ophthalmology
- Pharmacology
Context:
- Glaucoma treatment has evolved significantly over the past decade.
- Traditional short-acting cholinergic agonists are being superseded by newer drug classes.
Purpose:
- To review the pharmacological basis of current and future glaucoma treatments.
- To highlight the shift in drug of choice for lowering intra-ocular pressure.
Summary:
- Beta-blockers, specifically timolol maleate, are now the primary pharmacotherapy for glaucoma.
- Carbonic anhydrase inhibitors and prostaglandin analogues are emerging as promising treatments, currently in phase III trials.
Impact:
- Provides an overview of established and novel pharmacological strategies for glaucoma management.
- Informs clinicians and researchers about the evolving landscape of glaucoma pharmacotherapy.